Skip to main content
. 2020 Mar 3;34(2):757–765. doi: 10.21873/invivo.11835

Table I. Patient characteristics at baseline (N=236).

graphic file with name in_vivo-34-758-i0001.jpg

CT: Computed tomography; ECOG: Eastern Cooperative Oncology Group; MRI: magnetic resonance imaging; PSA: prostate specific antigen; *D’Amico risk categories: Low-risk: Gleason score <6, PSA <10 ng/ml and clinical stage T1c or T2a; intermediate-risk: Gleason score 7 or PSA 10-20 ng/ml or clinical stage T2b; high risk: Gleason score 8-10 or PSA >20 ng/ml or clinical stage T2c, T3, T4.